Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIZENS FINANCIAL GROUP INC/RICFG · Entity 1913 | Director | February 14, 2019 | February 15, 2019 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIZENS FINANCIAL GROUP INC/RI
Report date February 14, 2019 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,993.604 |
Reported balance
After 2019-02-14 transaction · row 1
1 source rowRow 1 · 2019-02-14 · Grant · Acquired 30.91 · Balance 60,993.604 F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan.
REGENERON PHARMACEUTICALS, INC.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,303 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Sale · Disposed 200 · Balance 17,303 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $767.44 | $4,604.64 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 15 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,282 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on December 1, 2022 at prices ranging from $767.20 to $767.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2022 at each separate price. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $766.39 | $4,598.34 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,288 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on December 1, 2022 at prices ranging from $766.05 to $766.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2022 at each separate price. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $765.70 | $2,297.10 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,294 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on December 1, 2022 at prices ranging from $765.49 to $765.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2022 at each separate price. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $764.61 | $1,529.22 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,297 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $763.28 | $2,289.84 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,299 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on December 1, 2022 at prices ranging from $763.25 to $763.30. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2022 at each separate price. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $762.57 | $762.57 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,302 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $761.56 | $4,569.36 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,303 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on December 1, 2022 at prices ranging from $761.29 to $761.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2022 at each separate price. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $759.67 | $1,519.34 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,309 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on December 1, 2022 at prices ranging from $759.36 to $759.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2022 at each separate price. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $758.39 | $2,275.17 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,311 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on December 1, 2022 at prices ranging from $758.03 to $758.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2022 at each separate price. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $757.60 | $3,788.00 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,314 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on December 1, 2022 at prices ranging from $757.02 to $757.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2022 at each separate price. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 20 | $756.35 | $15,127.00 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,319 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 20 shares of Company stock on December 1, 2022 at prices ranging from $756.10 to $756.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2022 at each separate price. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 26 | $755.47 | $19,642.22 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,339 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 26 shares of Company stock on December 1, 2022 at prices ranging from $755.00 to $755.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2022 at each separate price. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $754.61 | $5,282.27 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,365 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on December 1, 2022 at prices ranging from $754.49 to $754.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2022 at each separate price. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $753.53 | $5,274.71 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,372 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on December 1, 2022 at prices ranging from $753.40 to $753.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2022 at each separate price. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $752.57 | $2,257.71 |
DisclosureSEC source: 0001883850-22-000104 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,379 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $761.00 | $1,522.00 |
DisclosureSEC source: 0001883850-22-000088 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,382 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $759.61 | $3,798.05 |
DisclosureSEC source: 0001883850-22-000088 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,384 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on November 1, 2022 at prices ranging from $759.00 to $759.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2022 at each separate price. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $758.16 | $3,032.64 |
DisclosureSEC source: 0001883850-22-000088 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,389 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on November 1, 2022 at prices ranging from $758.05 to $758.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2022 at each separate price. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 15 | $757.58 | $11,363.70 |
DisclosureSEC source: 0001883850-22-000088 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,393 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 15 shares of Company stock on November 1, 2022 at prices ranging from $757.00 to $757.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2022 at each separate price. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 26 | $756.31 | $19,664.06 |
DisclosureSEC source: 0001883850-22-000088 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,408 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 26 shares of Company stock on November 1, 2022 at prices ranging from $756.01 to $756.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2022 at each separate price. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18 | $755.50 | $13,599.00 |
DisclosureSEC source: 0001883850-22-000088 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,434 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 18 shares of Company stock on November 1, 2022 at prices ranging from $755.11 to $755.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2022 at each separate price. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $754.73 | $9,056.76 |
DisclosureSEC source: 0001883850-22-000088 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,452 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 12 shares of Company stock on November 1, 2022 at prices ranging from $754.06 to $754.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2022 at each separate price. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $753.68 | $7,536.80 |
DisclosureSEC source: 0001883850-22-000088 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,464 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on November 1, 2022 at prices ranging from $753.23 to $753.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2022 at each separate price. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $752.59 | $4,515.54 |
DisclosureSEC source: 0001883850-22-000088 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,474 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on November 1, 2022 at prices ranging from $752.28 to $752.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2022 at each separate price. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $750.00 | $1,500.00 |
DisclosureSEC source: 0001883850-22-000088 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,480 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 24 | $733.64 | $17,607.36 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,482 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 24 shares of Company stock on October 3, 2022 at prices ranging from $733.12 to $733.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 3, 2022 at each separate price. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $732.47 | $5,127.29 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,506 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on October 3, 2022 at prices ranging from $732.00 to $732.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 3, 2022 at each separate price. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $731.49 | $4,388.94 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,513 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on October 3, 2022 at prices ranging from $731.43 to $731.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 3, 2022 at each separate price. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $730.00 | $1,460.00 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,519 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 19 | $728.23 | $13,836.37 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,521 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 19 shares of Company stock on October 3, 2022 at prices ranging from $728.03 to $728.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 3, 2022 at each separate price. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18 | $727.52 | $13,095.36 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,540 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 18 shares of Company stock on October 3, 2022 at prices ranging from $727.48 to $727.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 3, 2022 at each separate price. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $726.03 | $726.03 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,558 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $718.48 | $2,155.44 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,559 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $717.87 | $1,435.74 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,562 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $715.94 | $4,295.64 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,564 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on October 3, 2022 at prices ranging from $715.91 to $715.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 3, 2022 at each separate price. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $714.08 | $1,428.16 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,570 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $711.00 | $3,555.00 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,572 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $710.73 | $2,132.19 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,577 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $705.39 | $1,410.78 |
DisclosureSEC source: 0001883850-22-000076 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,580 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $587.23 | $1,761.69 |
DisclosureSEC source: 0001883850-22-000064 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,582 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on September 6, 2022 at prices ranging from $587.04 to $587.34. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $586.31 | $4,690.48 |
DisclosureSEC source: 0001883850-22-000064 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,585 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on September 6, 2022 at prices ranging from $586.14 to $586.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 16 | $585.58 | $9,369.28 |
DisclosureSEC source: 0001883850-22-000064 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,593 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 16 shares of Company stock on September 6, 2022 at prices ranging from $585.12 to $585.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $584.77 | $3,508.62 |
DisclosureSEC source: 0001883850-22-000064 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,609 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on September 6, 2022 at prices ranging from $584.57 to $584.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11 | $583.45 | $6,417.95 |
DisclosureSEC source: 0001883850-22-000064 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,615 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 11 shares of Company stock on September 6, 2022 at prices ranging from $583.12 to $583.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $582.51 | $4,660.08 |
DisclosureSEC source: 0001883850-22-000064 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,626 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on September 6, 2022 at prices ranging from $582.37 to $582.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14 | $581.46 | $8,140.44 |
DisclosureSEC source: 0001883850-22-000064 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,634 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 14 shares of Company stock on September 6, 2022 at prices ranging from $581.14 to $581.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $580.75 | $5,226.75 |
DisclosureSEC source: 0001883850-22-000064 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,648 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on September 6, 2022 at prices ranging from $580.50 to $580.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $579.67 | $4,057.69 |
DisclosureSEC source: 0001883850-22-000064 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,657 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on September 6, 2022 at prices ranging from $579.19 to $579.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11 | $578.56 | $6,364.16 |
DisclosureSEC source: 0001883850-22-000064 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,664 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 11 shares of Company stock on September 6, 2022 at prices ranging from $578.19 to $578.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $577.26 | $2,309.04 |
DisclosureSEC source: 0001883850-22-000064 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,675 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on September 6, 2022 at prices ranging from $577.14 to $577.37. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.